Sat, Apr 19, 2014, 1:32 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Alnylam Pharmaceuticals, Inc. Message Board

  • molinskym molinskym Sep 30, 2004 5:05 PM Flag

    Intellectual property

    Anyone want to comment on intellectual property issues? I can't find any info on the U.S. Patent and Trademark Office's on-line system, which lists patents awarded and new patent applications.

    Comments?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Thanks very much for the information, appreciate it.

    • Change in Directors or Principal Officers
      Hope this doesn't have any adverse affect. I wonder why he's resigning?

      Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

      (b) On September 29, 2004, Christoph H. Westphal, M.D., Ph.D., a director of Alnylam Pharmaceuticals, Inc. ("Alnylam"), informed Alnylam that he was resigning from the board of directors of Alnylam effective October 14, 2004.

    • I think the intelectual patent issues may turn out to be somewhat messy, if only because this field became so hot so fast. Some of the early patents may be too broad or weren't not written with sufficient care. This is just a guess however.

      Also, many companies will eventullay have to license patents from ALNY and others. For example:

      >>Monday February 2, 8:08 am ET

      BOTHELL, Wash., Feb. 2 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK - News), a leader in drug delivery technology, announced today that it has received a world-wide, non-exclusive license to the Fire et al. PATENTs and PATENT applications titled "Genetic Inhibition by Double-Stranded RNA" (including U.S. PATENT # 6,506,559 B1) from the Carnegie Institute of Washington, D.C. Under this license, Nastech plans to use the small interfering RNA (siRNA) technology in tight junction research and to develop therapeutics based upon siRNA technology. As the seminal description of RNA interference (RNAI), these PATENTs are considered fundamental to the field, as they broadly cover processes for introducing small interfering RNA into cells to control gene expression. <<

 
ALNY
53.86-0.75(-1.37%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Weibo Corporation
NasdaqGSThu, Apr 17, 2014 4:00 PM EDT